Sjölund M, de la Fuente A J Martín, Fossum C, Wallgren P
National Veterinary Institute, Department of Animal Health and Antimicrobial Strategies, SE-751 89 Uppsala, Sweden.
Vet Rec. 2009 May 2;164(18):550-5. doi: 10.1136/vr.164.18.550.
Four groups of six specific pathogen-free (SPF) pigs were inoculated intranasally with Actinobacillus pleuropneumoniae serotype 2 and treated with either enrofloxacin, tetracycline or penicillin at the onset of clinical disease, or left untreated. A fifth group was left uninoculated. The inoculated control and the penicillin-treated groups developed severe disease, but the groups treated with enrofloxacin and tetracycline recovered rapidly. All the inoculated pigs, except those treated with enrofloxacin developed serum antibodies to A pleuropneumoniae. On day 28, all five groups were challenged with A pleuropneumoniae without any subsequent treatment. The previously uninoculated control group and the enrofloxacin-treated group developed severe disease, but the three seropositive groups remained unaffected.
将四组每组六头的无特定病原体（SPF）猪经鼻接种胸膜肺炎放线杆菌2型，并在临床疾病发作时分别用恩诺沙星、四环素或青霉素进行治疗，或不进行治疗。第五组不进行接种。接种对照组和青霉素治疗组病情严重，但恩诺沙星和四环素治疗组恢复迅速。除恩诺沙星治疗的猪外，所有接种猪均产生了针对胸膜肺炎放线杆菌的血清抗体。在第28天，对所有五组猪在不进行后续治疗的情况下用胸膜肺炎放线杆菌进行攻毒。先前未接种的对照组和恩诺沙星治疗组病情严重，但三个血清阳性组未受影响。
